- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03269630
New Orleans Pulmonary Hypertension Biobank (NO-PH Biobank)
September 9, 2021 updated by: Matthew Lammi, Louisiana State University Health Sciences Center in New Orleans
Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure >=25mmHg on right heart catheterization (RHC).
Despite advances in PH care, outcomes are still sub-optimal and further research is required into the pathobiology of the disease and development of biomarkers that can guide clinical care.
The investigators are establishing a biobank to collect samples (blood, urine, stool) from patients with pulmonary hypertension, patients at high risk for pulmonary hypertension, healthy controls, and patients undergoing right heart catheterization.
Specimens will be stored for future investigations.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
450
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Matthew R Lammi, MD, MSCR
- Phone Number: 5045684634
- Email: mlammi@lsuhsc.edu
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- University Medical Center-New Orleans
-
Contact:
- Matthew Lammi, MD, MSCR
- Phone Number: 504-568-4634
- Email: mlammi@lsuhsc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects will be enrolled from 2 venues: 1) Comprehensive Pulmonary Hypertension Center clinic (pulmonary hypertension, systemic sclerosis without PH, mixed connective tissue disease without PH) and 2) Outpatient right heart catheterization lab.
Healthy subjects (age>18, not currently smoking, no chronic medical conditions) will also be enrolled.
Description
Inclusion Criteria:
- Diagnosis of pulmonary hypertension and followed at the Comprehensive Pulmonary Hypertension Center OR
- Diagnosis of systemic sclerosis and followed at the Comprehensive Pulmonary Hypertension Center OR
- Diagnosis of mixed connective tissue disease and followed at the Comprehensive Pulmonary Hypertension Center OR
- Undergoing outpatient right heart catheterization
Exclusion Criteria:
- Age<18
- Pregnant
- Unable to understand English
- Currently incarcerated
- Unwilling or unable to sign informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Clinic patients (Comprehensive Pulmonary Hypertension Center)
|
Biospecimen collection
|
|
Outpatient right heart catheterization patients
-Outpatients undergoing right heart catheterization for any indication
|
Biospecimen collection
|
|
Healthy controls
|
Biospecimen collection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Collection of biospecimens
Time Frame: 10 years
|
Biospecimen collection only
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 29, 2017
Primary Completion (Anticipated)
October 1, 2027
Study Completion (Anticipated)
October 1, 2027
Study Registration Dates
First Submitted
August 29, 2017
First Submitted That Met QC Criteria
August 30, 2017
First Posted (Actual)
September 1, 2017
Study Record Updates
Last Update Posted (Actual)
September 10, 2021
Last Update Submitted That Met QC Criteria
September 9, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LSU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
A sharing plan will be developed to share biospecimens with interested researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.